SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Coronavirus / COVID-19 Pandemic
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Moonray5/13/2020 10:20:48 PM
1 Recommendation

Recommended By
Stock Puppy

   of 22883
 
Japan’s Takeda says treatment trial using
recovered patients’ blood could start in July
Saheli Roy Choudhury

Japan’s Takeda Pharmaceutical said it could begin
a clinical trial for a potential treatment as early as
July, Reuters reported. The treatment would be
based on antibodies from people who have
recovered, the news agency said, citing Takeda
executives.

If the trial, which would include hundreds of patients,
succeeds, then Takeda could file for approval by U.S.
authorities later this year, according to Reuters. Still, T
akeda said the treatment’s availability beyond the
clinical study remains “a bit unclear.”

o~~~ O
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News